SensoDetect

Prototype transfer & AI upgrade

A BERA prototype device produced through the joint-venture structure is now being prepared for shipment to Sweden for

• final quality review,

• firmware refinement,

• and integration of the new AI release.

This process reinforces Sweden as the Company’s central AI development and quality-control hub.

Expanding collaborations in China

Engagement continues to expand across

• regional hospitals (separate regions),

• school systems (multiple regions),

• industrial groups (aviation & security),

• local & central authorities,

• and new potential collaborators and investors.

Cooperation discussions have now also expanded to university-level AI collaboration, including joint workstreams within

• AI research,

• neural signal modelling,

• and data-driven screening development.

Leadership & Expertise Supporting Execution in China

SensoDetect’s joint-venture initiative in Beijing continues to be reinforced by experienced leadership.

Mr. Lu Zhong – Chairman

Over 20 years senior leadership experience across Microsoft China, Oracle China, AMD Greater China and Alibaba Group; Chairman of Zhonghai Investment and Zhonghai Accelerator, with Executive MBA studies at CKGSB and Tsinghua PBC School of Finance. His background provides strong commercial and governmental capability in China. 

“We are building something responsible, long-term and aligned with the needs of hospitals, families and society. Our confidence in this collaboration continues to grow.”

Mr. Lu Weihua – Director

Licensed securities attorney with 16+ years’ experience across law, M&A, restructuring and business development, and General Manager of Beijing Kuntian Liren Medical Technology. He strengthens legal governance, compliance, and operational execution of the JV.

“We are strengthening governance, partnerships and the structures required for sustainable rollout. Each step is taken with clarity and purpose.”

Dr. Liu Hai – Medical Expert

Chief Physician and Associate Professor at Beijing Tiantan Hospital and Capital Medical University, with training at University of Rochester and University of Washington and leadership roles in national neurosurgical committees. He reinforces clinical rigor and scientific credibility for the JV.

“Our goal is to advance objective, clinically sound tools that improve the journey for children and families. We are progressing steadily and responsibly.”

Outlook China 2026 and beyond

SensoDetect’s China roadmap prioritises

• clinical legitimacy,

• university collaboration,

• regulatory alignment,

• responsible scaling,

• and strong long-term partnerships.

PA Hedin – JV Board member and CEO, SensoDetect AB

“As we build our presence in China, we are guided by what truly creates long-term value: trust, reputation, shared development, regulatory responsibility and disciplined, long-cycle execution. Our focus is on deep cooperation with hospitals, universities and authorities, and on scaling our technology responsibly and with quality at its core. This is how durable value is created in China, and SensoDetect is fully aligned with that approach. 2026 will be the year where the groundwork begins to translate into tangible commercial returns, with 2027 positioned for accelerated revenue expansion and increasing profitability.”